ctDNA kinetics during therapy and clinical outcomes (A) The median and range of quantitative ctDNA levels after each cycle of therapy until treatment is complete. Levels of ctDNA in patients with ALK⁺ ALCL are depicted with green dots, and levels in other histologic subtypes of PTCL are depicted with black dots. (B) EFS based on presence or absence of ctDNA as a marker of MRD, drawn before day 1 of cycle 3. (C) OS based on the presence or absence of ctDNA as a marker of MRD drawn before day 1 of cycle 3. (D) EFS based on the presence or absence of ctDNA as a marker of MRD at the EoT. (E) OS based on presence or absence of ctDNA as a marker of MRD at EoT. C, cycle.